RPE65 and Leber congenital amaurosis: The success of the RPE65−/− dog gene therapy experiments was crucial in the development of human clinical trials to treat patients affected with Leber congenital amaurosis (LCA) or early onset retinal degeneration linked to a mutation in RPE65 [4-6].